# Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

> **NCT00440622** · PHASE3 · TERMINATED · sponsor: **Hellenic Oncology Research Group** · enrollment: 90 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Herceptin
- **DRUG:** Capecitabine (Xeloda)

## Key facts

- **NCT ID:** NCT00440622
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-04
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 90 (ACTUAL)
- **Why stopped:** Due to poor accrual
- **Last updated:** 2013-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00440622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00440622, "Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00440622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*